Apomorphine: A rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease

Clinical Neuropharmacology

Volumn 29, Issue 5, 2006, Pages 292-301

  Kolls, Brad J ^a   Stacy, Mark ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apomorphine; Injectable therapy; Motor fluctuations; Parkinson disease; Treatments

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

BRADYCARDIA; CLINICAL TRIAL; DEATH; DEGENERATIVE DISEASE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSKINESIA; FAINTNESS; HALLUCINATION; HUMAN; HYPOTENSION; INJECTION SITE NODULE; INJECTION SITE REACTION; INJECTION SITE ULCER; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VOMITING; YAWNING;

ANTIPARKINSON AGENTS; APOMORPHINE; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE;

EID: 33748981339     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000220824.57769.E5     Document Type: Review

References (47)

1. Rajput ML. Epidemiology of Parkinsonism. New York, NY: Demos; 2002.
2. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43(8):1459-1464.
3. Neumeyer JLLS, Baldessarini RJ. Historical Highlights of the Chemistry Pharmacology and Early Cliknical Uses of Apomorphine. New York, NY: Raven Press; 1981.
4. Goldman ME, Kebabian JW. Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors. Mol Pharmacol 1984;25(1):18-23.
5. Hutchinson WD, Levy R, Dostrovsky JO, et al. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 1997;42(5):767-775.
6. Factor SA. Dopamine agonists. Med Clin North Am 1999;83(2):415-443. vi-vii.
7. Levy R, Dostrovsky JO, Lang AE, et al. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 2001;86(1):249-260.
8. Lozano AM, Lang AE, Levy R, et al. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 2000;47(4 suppl 1):S141-S146.
9. Hofstee DJ, Neef C, van Laar T, et al. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 1994;17(1):45-52.
10. Zijlmans JC, Debilly B, Rascol O, et al. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord 2004;19(9):1006-1011.
11. Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord 1995;10(1):28-36.
12. Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 2004;62(6 suppl 4):S22-S26.
13. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993;7(3-4):121-128.
14. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004;62(6 suppl 4):S8-S11.
15. Sam E, Augustijns P, Verbeke N. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994;658(2):311-317.
16. van der Geest R, van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin Neuropharmacol 1998;21(3):159-168.
17. Sam E, Jeanjean AP, Maloteaux JM, et al. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;20(1):27-33.
18. Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord 2000;6(4):237-240.
19. Rehse K, Piesker G, Horowski R. Neuropsychotropic activity and toxicity of oxidation products of apomorphine. Arch Pharm (Weinheim) 1978;311(4):360-363.
20. Schwab RSAL, Lettvin JY. Apomorphine in Parkinson's Disease. Trans Am Neurol Assoc 1951;76:252-255.
21. Kapoor R, Turjanski N, Frankel J, et al. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53(11):1015.
22. Dewey RB Jr, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58(9):1385-1392.
23. Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48(2):369-372.
24. Bottini PSA, Huang M-Y, Sherry JH. Apomorphine pharmacokinetic- pharmacodynamic correlations following single and repeated subcutaneous injections in patients with Parkinson's disease. Mov Disord 2002;17(5 suppl):S101.
25. Liao SLM, Shaw A, Huang M. Population pharmacokinetic/pharmacodynamic models for motor response of apomorphine in patients with idiopathic Parkinson's disease. AAPS Pharm Sci 2002;4:R6219.
26. Sherry JHGP, van Lunen B, Bottini PB. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease. Neurology 2003;60(1 suppl):A81.
27. Merello M, Pikielny R, Cammarota A, et al. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997;20(2):165-167.
28. Cotzias GC, Papavasiliou PS, Fehling C, et al. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970;282(1):31-33.
29. Duby SE, Cotzias GC, Papavasiliou PS, et al. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol 1972;27(6):474-480.
30. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984;107(Pt 2):487-506.
31. van Laar T, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95(3):231-235.
32. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58(6):681-687.
33. Gervason CL, Pollak PR, Limousin P, et al. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease. Clin Neuropharmacol 1993;16(2):113-119.
34. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8(2):165-170.
35. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990;336(8706):32-34.
36. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41(4):261-309.
37. Galvez-Jimenez N, Lang AE. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci 1996;23(3):198-203.
38. Hughes AJ, Lees AJ, Stern GM. Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin Neuropharmacol 1990;13(4):312-317.
39. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62(6 suppl 4):S32-S36.
40. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65(5):709-716.
41. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64(5):573-576.
42. Homann CN, Suppan K, Wenzel K, et al. Sleep attacks with apomorphine. Wien Klin Wochenschr 2002;114(10-11):430-431.
43. Stacy M. Apomorphine: North American clinical experience. Neurology 2004;62(6 suppl 4):S18-S21.
44. Provided NA. New drugs and dosage forms. Am J Health Syst Pharm 2004;61(14):1432.
45. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004;62(6 suppl 4):S12-S17.
46. Kanovsky P, Kubova D, Bares M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17(1):188-191.
47. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17(6):1235-1241.